PMC:7445716 / 43850-44106 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T225","span":{"begin":9,"end":13},"obj":"Body_part"},{"id":"T226","span":{"begin":24,"end":29},"obj":"Body_part"},{"id":"T227","span":{"begin":247,"end":252},"obj":"Body_part"}],"attributes":[{"id":"A225","pred":"fma_id","subj":"T225","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A226","pred":"fma_id","subj":"T226","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A227","pred":"fma_id","subj":"T227","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T121","span":{"begin":247,"end":252},"obj":"Body_part"}],"attributes":[{"id":"A121","pred":"uberon_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T466","span":{"begin":74,"end":78},"obj":"Disease"},{"id":"T467","span":{"begin":162,"end":164},"obj":"Disease"}],"attributes":[{"id":"A466","pred":"mondo_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"},{"id":"A467","pred":"mondo_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/MONDO_0007886"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T273","span":{"begin":9,"end":13},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T274","span":{"begin":21,"end":29},"obj":"http://purl.obolibrary.org/obo/CLO_0001921"},{"id":"T275","span":{"begin":234,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T276","span":{"begin":247,"end":252},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T239","span":{"begin":79,"end":81},"obj":"Chemical"},{"id":"T240","span":{"begin":126,"end":135},"obj":"Chemical"},{"id":"T241","span":{"begin":137,"end":146},"obj":"Chemical"},{"id":"T242","span":{"begin":169,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A240","pred":"chebi_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A241","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_73531"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PubTator","denotations":[{"id":"883","span":{"begin":59,"end":77},"obj":"Disease"},{"id":"884","span":{"begin":168,"end":179},"obj":"Disease"},{"id":"885","span":{"begin":196,"end":224},"obj":"Disease"}],"attributes":[{"id":"A884","pred":"tao:has_database_id","subj":"884","obj":"MESH:D018908"},{"id":"A885","pred":"tao:has_database_id","subj":"885","obj":"MESH:C531747"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-sentences","denotations":[{"id":"T225","span":{"begin":21,"end":73},"obj":"Sentence"},{"id":"T226","span":{"begin":74,"end":212},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T644","span":{"begin":60,"end":73},"obj":"Phenotype"},{"id":"T645","span":{"begin":197,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A644","pred":"hp_id","subj":"T644","obj":"http://purl.obolibrary.org/obo/HP_0011096"},{"id":"A645","pred":"hp_id","subj":"T645","obj":"http://purl.obolibrary.org/obo/HP_0001349"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T434","span":{"begin":106,"end":124},"obj":"CHEBI:5801;CHEBI:5801;DG_20"},{"id":"T435","span":{"begin":126,"end":135},"obj":"DG_30"},{"id":"T436","span":{"begin":197,"end":203},"obj":"UBERON:0001456"},{"id":"T437","span":{"begin":247,"end":252},"obj":"UBERON:0001443"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}

{"project":"2_test","denotations":[{"id":"32840686-32334841-63205757","span":{"begin":233,"end":235},"obj":"32334841"}],"text":"ncreased cell count: 13 cells/mm3, polymorphonucleate 61.5% Demyelinating\nAIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia\nCamdessanche et al. [11] RT-PCR + chest CT "}